{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:41Z","timestamp":1787020841263,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Angiogenesis plays a central role in the pathophysiology of rheumatic diseases. Patients with psoriatic arthritis (PsA) demonstrate increased vascularity over patients with rheumatoid arthritis (RA), with unknown mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated the serum levels of several pro- and anti-angiogenic factors in 62 PsA patients with active disease, 39 PsA patients in remission, 33 active RA patients, and 33 healthy controls (HC). Additionally, we used an in vitro co-culture system of fibroblast (HT1080) and monocytic-like (MM6) cell lines, to evaluate how their interactions affect the secretion of angiogenic factors and angiogenesis promoting abilities using scratch and tube formation assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PsA patients, regardless of disease activity, exhibited higher levels of EMMPRIN\/CD147, IL-17, and TNF-\u03b1 relative to RA patients or HC. Factors, such as IL-6, and the ratio between CD147 and thrombospondin-1, exhibited elevated levels in active PsA patients relative to PsA patients in remission. Secretion of CD147, VEGF, and MMP-9 was increased in vitro. CD147 neutralization with an antibody reduced these levels and the ability of endothelial cells to form tube-like structures or participate in wound healing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CD147 plays a role in mediating angiogenesis in PsA, and the therapeutic possibilities of neutralizing it merit further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-020-02333-6","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T04:07:12Z","timestamp":1602648432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The role of EMMPRIN\/CD147 in regulating angiogenesis in patients with psoriatic arthritis"],"prefix":"10.1186","volume":"22","author":[{"given":"Michal A.","family":"Rahat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirna","family":"Safieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Simanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliran","family":"Pasand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Gazitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0523-2292","authenticated-orcid":false,"given":"Devy","family":"Zisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,14]]},"reference":[{"key":"2333_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2045-824X-5-11","volume":"5","author":"N Maruotti","year":"2013","unstructured":"Maruotti N, Annese T, Cantatore FP, Ribatti D. Macrophages and angiogenesis in rheumatic diseases. Vasc Cell. 2013;5:1\u20138.","journal-title":"Vasc Cell"},{"key":"2333_CR2","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1136\/ard.2009.119776","volume":"69","author":"C Ng","year":"2010","unstructured":"Ng C, Biniecka M, Kennedy A, McCormick J, FitGerald O, Bresnihan B, et al. Synovial tissue hypoxia and inflammation in vivo. Ann Rheum Dis. 2010;69:1389\u201395 Available from: http:\/\/ard.bmj.com. [cited 2019 Mar 11].","journal-title":"Ann Rheum Dis"},{"key":"2333_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2014-000025","volume":"1","author":"DJ Veale","year":"2015","unstructured":"Veale DJ, Fearon U. What makes psoriatic and rheumatoid arthritis so different? RMD Open. 2015;1:1\u20135.","journal-title":"RMD Open"},{"key":"2333_CR4","doi-asserted-by":"crossref","unstructured":"Cantatore FP, Maruotti N, Corrado A, Ribatti D. Angiogenesis dysregulation in psoriatic arthritis: molecular mechanisms. Biomed Res Int. 2017;2017:Article ID 5312813, 6.","DOI":"10.1155\/2017\/5312813"},{"key":"2333_CR5","doi-asserted-by":"crossref","unstructured":"Yamamoto T. Angiogenic and inflammatory properties of psoriatic arthritis. ISRN Dermatol. 2013;2013:Article ID 630620, 7. Available from: http:\/\/www.hindawi.com\/journals\/isrn\/2013\/630620\/.","DOI":"10.1155\/2013\/630620"},{"key":"2333_CR6","doi-asserted-by":"publisher","unstructured":"Zimna A, Kurpisz M. Hypoxia-inducible factor-1 in physiological and pathophysiological angiogenesis: applications and therapies. Biomed Res Int 2015;2015:Article ID 549412, 13 pages. https:\/\/doi.org\/10.1155\/2015\/549412. [cited 2019 Mar 11].","DOI":"10.1155\/2015\/549412"},{"key":"2333_CR7","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/art.24844","volume":"60","author":"MJ Del Rey","year":"2009","unstructured":"Del Rey MJ, Izquierdo E, Caja S, Usategui A, Santiago B, Galindo M, et al. Human inflammatory synovial fibroblasts induce enhanced myeloid cell recruitment and angiogenesis through a hypoxia-inducible transcription factor 1\u03b1\/vascular endothelial growth factor-mediated pathway in immunodeficient mice. Arthritis Rheum. 2009;60:2926\u201334.","journal-title":"Arthritis Rheum"},{"key":"2333_CR8","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391:2273\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(18)30830-4.","journal-title":"Lancet"},{"key":"2333_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41584-018-0044-2","volume":"14","author":"LS Taams","year":"2018","unstructured":"Taams LS, Steel KJA, Srenathan U, Burns LA, Kirkham BW. IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol. 2018;14:453\u201366. https:\/\/doi.org\/10.1038\/s41584-018-0044-2.","journal-title":"Nat Rev Rheumatol"},{"key":"2333_CR10","doi-asserted-by":"publisher","unstructured":"Malemud CJ. Matrix metalloproteinases and synovial joint pathology. In: Khalil RA, editor. Matrix Met Tissue Remodel Heal Dis Target Tissues Ther. 1st ed. Elsevier Inc.; 2017. p. 305\u201325. https:\/\/doi.org\/10.1016\/bs.pmbts.2017.03.003.","DOI":"10.1016\/bs.pmbts.2017.03.003"},{"key":"2333_CR11","doi-asserted-by":"publisher","unstructured":"Grass GD, Toole BP. How, with whom and when: an overview of CD147-mediated regulatory networks influencing matrix metalloproteinase activity. Biosci Rep. 2016;36:Article e00283 (16 pages). doi: https:\/\/doi.org\/10.1042\/BSR20150256.","DOI":"10.1042\/BSR20150256"},{"key":"2333_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1365-2249.2010.04115.x","volume":"160","author":"V Yurchenko","year":"2010","unstructured":"Yurchenko V, Constant S, Eisenmesser E, Bukrinsky M. Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics. Clin Exp Immunol. 2010;160:305\u201317 Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=2883100&tool=pmcentrez&rendertype=abstract. [cited 2015 Dec 15].","journal-title":"Clin Exp Immunol"},{"key":"2333_CR13","first-page":"157","volume":"7","author":"UH Weidle","year":"2010","unstructured":"Weidle UH, Scheuer W, Eggle D, Klostermann S, Stockinger H. Cancer-related issues of CD147. Cancer Genomics Proteomics. 2010;7:157\u201369 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20551248. [cited 2016 Jan 28].","journal-title":"Cancer Genomics Proteomics"},{"key":"2333_CR14","first-page":"16","volume":"178","author":"B-C Amit-Cohen","year":"2013","unstructured":"Amit-Cohen B-C, Rahat MM, Rahat MA. Tumor cell-macrophage interactions increase angiogenesis through secretion of EMMPRIN. Front Physiol. 2013;178:16 Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3709141&tool=pmcentrez&rendertype=abstract. [cited 2016 Jan 27].","journal-title":"Front Physiol"},{"key":"2333_CR15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ejphar.2012.10.030","volume":"698","author":"J Huang","year":"2013","unstructured":"Huang J, Xie B, Li Q, Xie X, Zhu S, Wang M, et al. Infliximab reduces CD147, MMP-3, and MMP-9 expression in peripheral blood monocytes in patients with active rheumatoid arthritis. Eur J Pharmacol. 2013;698:429\u201334. https:\/\/doi.org\/10.1016\/j.ejphar.2012.10.030.","journal-title":"Eur J Pharmacol"},{"key":"2333_CR16","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1346-8138.2010.00935.x","volume":"37","author":"H Lu","year":"2010","unstructured":"Lu H, Kuang YH, Su J, Chang J, Wu LS, Kanekura T, et al. CD147 is highly expressed on peripheral blood neutrophils from patients with psoriasis and induces neutrophil chemotaxis. J Dermatol. 2010;37:1053\u20136.","journal-title":"J Dermatol"},{"key":"2333_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep44172","volume":"7","author":"C Peng","year":"2017","unstructured":"Peng C, Zhang S, Lei L, Zhang X, Jia X, Luo Z, et al. Epidermal CD147 expression plays a key role in IL-22-induced psoriatic dermatitis. Sci Rep. 2017;7:1\u201314. https:\/\/doi.org\/10.1038\/srep44172.","journal-title":"Sci Rep"},{"key":"2333_CR18","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1002\/art.34341","volume":"64","author":"CH Wang","year":"2012","unstructured":"Wang CH, Yao H, Chen LN, Jia JF, Wang L, Dai JY, et al. CD147 induces angiogenesis through a vascular endothelial growth factor and hypoxia-inducible transcription factor 1\u03b1-mediated pathway in rheumatoid arthritis. Arthritis Rheum. 2012;64:1818\u201327.","journal-title":"Arthritis Rheum"},{"key":"2333_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/apm.12629","volume":"125","author":"H Yang","year":"2017","unstructured":"Yang H, Wang J, Li Y, Yin Z-J, Lv T-T, Zhu P, et al. CD147 modulates the differentiation of T-helper 17 cells in patients with rheumatoid arthritis. APMIS. 2017;125:24\u201331 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27859685. [cited 2018 Dec 5].","journal-title":"APMIS"},{"key":"2333_CR20","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665\u201373.","journal-title":"Arthritis Rheum"},{"key":"2333_CR21","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580\u20138 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20699241. [cited 2017 May 24].","journal-title":"Ann Rheum Dis"},{"key":"2333_CR22","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"2333_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48\u201353. https:\/\/doi.org\/10.1136\/ard.2008.102053.","journal-title":"Ann Rheum Dis"},{"key":"2333_CR24","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75:811\u20138.","journal-title":"Ann Rheum Dis"},{"key":"2333_CR25","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1136\/annrheumdis-2012-201491","volume":"71","author":"D Aletaha","year":"2012","unstructured":"Aletaha D, Martinez-Avila J, Kvien TK, Smolen JS. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Ann Rheum Dis. 2012;71:1190\u20136.","journal-title":"Ann Rheum Dis"},{"key":"2333_CR26","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1053\/sarh.2002.50004","volume":"32","author":"JD Ca\u00f1ete","year":"2003","unstructured":"Ca\u00f1ete JD, Rodriguez JR, Salvador G, G\u00f3mez-Centeno A, Mu\u00f1oz-G\u00f3mez J, Sanmart\u00ed R. Diagnostic usefulness of synovial vascular morphology in chronic arthritis. A systematic survey of 100 cases. Semin Arthritis Rheum. 2003;32:378\u201387.","journal-title":"Semin Arthritis Rheum"},{"key":"2333_CR27","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1111\/1346-8138.14305","volume":"45","author":"M Gao","year":"2018","unstructured":"Gao M, Liao L, Jia X, Kuang Y, Chen X. Role of soluble CD147 in psoriatic patients: a preliminary study. J Dermatol. 2018;45:e266\u20137.","journal-title":"J Dermatol"},{"key":"2333_CR28","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1002\/art.34341","volume":"64","author":"CH Wang","year":"2012","unstructured":"Wang CH, Yao H, Chen LN, Jia JF, Wang L, Dai JY, et al. CD147 induces angiogenesis through a vascular endothelial growth factor and hypoxia-inducible transcription factor 1??-mediated pathway in rheumatoid arthritis. Arthritis Rheum. 2012;64:1818\u201327.","journal-title":"Arthritis Rheum"},{"key":"2333_CR29","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/j.1582-4934.2010.01084.x","volume":"15","author":"CH Wang","year":"2011","unstructured":"Wang CH, Dai JY, Wang L, Jia JF, Zheng ZH, Ding J, et al. Expression of CD147 (EMMPRIN) on neutrophils in rheumatoid arthritis enhances chemotaxis, matrix metalloproteinase production and invasiveness of synoviocytes. J Cell Mol Med. 2011;15:850\u201360.","journal-title":"J Cell Mol Med"},{"key":"2333_CR30","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.4161\/cc.24579","volume":"12","author":"MF Ghahremani","year":"2013","unstructured":"Ghahremani MF, Goossens S, Haigh JJ. The p53 family and VEGF regulation \u201cit\u2019s complicated.\u201d. Cell Cycle. 2013;12:1331\u20132.","journal-title":"Cell Cycle"},{"key":"2333_CR31","first-page":"238","volume":"31","author":"PA Klimiuk","year":"2004","unstructured":"Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J Rheumatol. 2004;31:238\u201342 Available from: http:\/\/www.embase.com\/search\/results?subaction=viewrecord&from=export&id=L38160743%0Ahttp:\/\/sfx.library.uu.nl\/utrecht?sid=EMBASE&issn=0315162X&id=doi:&atitle=Effect+of+Repeated+Infliximab+Therapy+on+Serum+Matrix+Metalloproteinases+and+Tissue+Inhibitors+of.","journal-title":"J Rheumatol"},{"key":"2333_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cyto.2005.12.009","volume":"33","author":"I Litinsky","year":"2006","unstructured":"Litinsky I, Paran D, Levartovsky D, Wigler I, Kaufman I, Yaron I, et al. The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. Cytokine. 2006;33:106\u201310.","journal-title":"Cytokine."},{"key":"2333_CR33","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00296-014-3112-1","volume":"35","author":"PA Klimiuk","year":"2015","unstructured":"Klimiuk PA, Domys\u0142awska I, Sierakowski S, Chwie\u0107ko J. Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers. Rheumatol Int. 2015;35:749\u201355.","journal-title":"Rheumatol Int"},{"key":"2333_CR34","first-page":"1523","volume":"33","author":"M Fiedorczyk","year":"2006","unstructured":"Fiedorczyk M, Klimiuk P, Sierakowski S, Gindzienska-Sieskiewicz E, Chwiecko J. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. J Rheumatol. 2006;33:1523\u20139.","journal-title":"J Rheumatol"},{"key":"2333_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1254\/jphs.12129SC","volume":"120","author":"T Kotani","year":"2012","unstructured":"Kotani T, Takeuchi T, Takai S, Yoshida S, Hata K, Nagai K, et al. Serum levels of matrix metalloproteinase (MMP) 9, a risk factor for acute coronary syndrome, are reduced independently of serum MMP-3 by anti-TNF-alpha antibody (infliximab) therapy in patients with rheumatoid arthritis. J Pharmacol Sci. 2012;120:50\u20133.","journal-title":"J Pharmacol Sci"},{"key":"2333_CR36","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1136\/ard.2010.129197","volume":"69","author":"MJ Barter","year":"2010","unstructured":"Barter MJ, Hui W, Lakey RL, Catterall JB, Cawston TE, Young DA. Lipophilic statins prevent matrix metalloproteinase-mediated cartilage collagen breakdown by inhibiting protein geranylgeranylation. Ann Rheum Dis. 2010;69:2189\u201398.","journal-title":"Ann Rheum Dis"},{"key":"2333_CR37","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1177\/0003319716688301","volume":"68","author":"G Ferretti","year":"2017","unstructured":"Ferretti G, Bacchetti T, Banach M, Simental-Mend\u00eda LE, Sahebkar A. Impact of statin therapy on plasma MMP-3, MMP-9, and TIMP-1 concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Angiology. 2017;68:850\u201362.","journal-title":"Angiology."},{"key":"2333_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-015-0756-5","volume":"17","author":"S Reiseter","year":"2015","unstructured":"Reiseter S, Molberg \u00d8, Gunnarsson R, Lund MB, Aalokken TM, Aukrust P, et al. Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study. Arthritis Res Ther. 2015;17:1\u20139. https:\/\/doi.org\/10.1186\/s13075-015-0756-5.","journal-title":"Arthritis Res Ther"},{"key":"2333_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejphar.2013.10.068","volume":"723","author":"XY Huang","year":"2014","unstructured":"Huang XY, Zhang XM, Chen FH, Zhou LL, Deng XF, Liu YJ, et al. Anti-proliferative effect of recombinant human endostatin on synovial fibroblasts in rats with adjuvant arthritis. Eur J Pharmacol. 2014;723:7\u201314. https:\/\/doi.org\/10.1016\/j.ejphar.2013.10.068.","journal-title":"Eur J Pharmacol"},{"key":"2333_CR40","first-page":"1","volume":"7","author":"N Chen","year":"2016","unstructured":"Chen N, Gao RF, Yuan FL, Zhao MD. Recombinant human endostatin suppresses mouse osteoclast formation by inhibiting the NF-\u03baB and MAPKs signaling pathways. Front Pharmacol. 2016;7:1\u201310.","journal-title":"Front Pharmacol"},{"key":"2333_CR41","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3899\/jrheum.141292","volume":"42","author":"T Suzuki","year":"2015","unstructured":"Suzuki T, Iwamoto N, Yamasaki S, Nishino A, Nakashima Y, Horai Y, et al. Upregulation of thrombospondin 1 expression in synovial tissues and plasma of rheumatoid arthritis: role of transforming growth factor-beta1 toward fibroblast-like synovial cells. J Rheumatol. 2015;42:943\u20137.","journal-title":"J Rheumatol"},{"key":"2333_CR42","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s10067-018-4188-x","volume":"37","author":"Y Meng","year":"2018","unstructured":"Meng Y, Zhao X, Cheng Y, Jia R, Sun X, Zhang M, et al. Decreased serum thrombospondin-1 and elevation of its autoantibody are associated with multiple exacerbated clinical manifestations in systemic lupus erythematosus. Clin Rheumatol Clinical Rheumatol. 2018;37:2707\u201314.","journal-title":"Clin Rheumatol Clinical Rheumatol"},{"key":"2333_CR43","doi-asserted-by":"publisher","first-page":"84546","DOI":"10.18632\/oncotarget.19165","volume":"8","author":"T Huang","year":"2017","unstructured":"Huang T, Sun L, Yuan X, Qiu H. Thrombospondin-1 is a multifaceted player in tumor progression. Oncotarget. 2017;8:84546\u201358.","journal-title":"Oncotarget."},{"key":"2333_CR44","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.lfs.2012.06.032","volume":"91","author":"J Lee","year":"2012","unstructured":"Lee J, Cooke JP. Nicotine and pathological angiogenesis. Life Sci. 2012;91:1058\u201364. https:\/\/doi.org\/10.1016\/j.lfs.2012.06.032.","journal-title":"Life Sci"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02333-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02333-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02333-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T20:24:00Z","timestamp":1634156640000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02333-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,14]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2333"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02333-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,14]]},"assertion":[{"value":"15 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research was reviewed and approved by the local Institutional Review Board at Carmel Medical Center (CMC-004411), and all participants signed informed consent before enrollment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"240"}}